Tafasitamab Adds Follicular Lymphoma Indication Free

The FDA approved tafasitamab (Monjuvi; Incyte) for patients with relapsed or refractory follicular lymphoma in combination with the immunomodulatory imide drug lenalidomide and the anti-CD20 mAb rituximab. Tafasitamab, a CD-19 targeting mAb, was approved for large B-cell lymphoma in July 2020. The decision to approve the drug for follicular lymphoma was based on results from the phase III inMIND study, in which patients received lenalidomide and rituximab and were randomly assigned to receive either tafasitamab or a placebo. Median PFS was 22.4 months in the tafasitamab group and 13.9 months in the placebo group.